Active Delta Referral — screening to care pathway
Official title: "Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.
Run by FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT07317011 · Data updated 2026-11-12
This project will try an automatic 'HDV-reflex' screening to find how common hepatitis D is among adults with hepatitis B who are hospitalized or served by addiction and prison health services in Bergamo.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 244 (estimated) |
| Sponsor | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Academic / other |
| Locations | 1 site (Bergamo) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 9, 2026 |
| Trial ID | NCT07317011 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) who are HBsAg-positive and hospitalized at ASST Papa Giovanni XXIII's Department of Medicine or attending its SerD or Prison Health Service, and who provide informed consent.
✕Probably not a fit
People who are HBsAg-negative, those receiving care outside the specified Bergamo sites, or individuals who do not provide informed consent are not expected to benefit from this screening initiative.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Hepatitis Delta is the most severe chronic viral hepatitis and occurs only in people who are HBsAg-positive, but it is often missed because routine automatic screening is not in place. Starting in 2025 the project will implement an 'HDV-reflex' test that automatically checks anti-HDV in HBsAg-positive adults at the Department of Medicine, the SerD, and the Prison Health Service of ASST Papa Giovanni XXIII in Bergamo. The team will estimate anti-HDV prevalence in these settings and compare the results with existing outpatient data. The program also intends to improve referral pathways to hepatology and enable earlier use of new antiviral treatment options.
Why it matters
Potential benefit: If successful, the approach could identify many previously undiagnosed HDV cases earlier, enabling timely treatment and reducing the number of patients presenting with advanced HDV-related liver disease.
How similar studies have gone: Reflex HDV screening strategies have been implemented successfully in other countries and have increased detection of HDV among HBV-positive patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥18 years. * Hospitalized at the Department of Medicine of ASST Papa Giovanni XXIII in Bergamo, or attending the SerD or the Penitentiary Health Service of Bergamo. * HBsAg positivity. * Obtaining informed consent. Exclusion Criteria: * Lack of informed consent
Where it's running
-
Asst Papa Giovanni Xxiii
Bergamo, Italy Recruiting
Study contacts
- Study coordinator: Eleonora Sfreddo
- Email: sperimentazioni@fondazionefrom.it
- Phone: +39 0352675134
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePro Diary for people with HDV (MACROLIVER)
This project will try a mobile ePro diary app to help adults with Delta hepatitis (HDV) track symptoms and share health information with their care team.
-
ELN multicenter analysis of phenotypic evolution and clinical outcomes
This study tries to find features linked to JAK2V617F-positive essential thrombocythemia (ET) patients who later developed polycythemia vera (PV) by comparing them with matched ET patients who did not progress and with patients diagnosed with de novo PV.
-
Investigating the role of clonal hematopoiesis in heart failure
This study looks at how changes in blood cell production might affect inflammation and heart problems in people with heart failure.
-
Observational study on patients with myelofibrosis in Europe
This study is collecting information from patients with myelofibrosis across Europe to better understand the disease and improve how it's diagnosed and treated.
-
Observing the effects of ropeginterferon alfa-2b in patients with Polycythemia Vera
This study is testing how well the drug ropeginterferon alfa-2b works and is tolerated by people with Polycythemia Vera who need treatment.
-
Digital tool for managing liver disease in young patients
This study is testing a new digital tool to help young people with liver disease manage their care better as they transition from pediatric to adult healthcare.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.